Obesity and the proinflammatory state are sufficiently tied to psoriasis and HS that GLP-1 agonists should be considered within multifaceted care, experts say.

Researchers conducted a pooled analysis of individual patient-level data from 15 trials assessing time to colon cancer-related relapse.